Testing of serum Kisspeptin and DLK1 levels in Central Precocious Puberty at Diagnosis and After Pubertal Suppressio

• Conditions: Central precocious puberty; Precocious puberty; Kisspeptin; DLK1; pubertal suppression

• Registration Number: TCTR20210901002
• Lead Sponsor: Ratchadapiseksompotch Research Fund

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-09-01
• Study Completion: 2022-04-01
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Pending (Not yet recruiting)
• Sex: Female
• Target Recruitment: 74

Inclusion Criteria

1. Girls
2. Diagnostic criteria of CPP
2.1 Girls with breast Tanner II before the age of 8 years
2.2 Peak LH from GnRH stimulation test more than 6 IU/L or baseline LH more than 0.3 IU/L
2.3 Bone age advancement more than one year

Exclusion Criteria

Congenital adrenal hyperplasia
Chronic diseases
Cerebral palsy
Post-insult: hydrocephalus, CNS infection, radiotherapy, chemotherapy
Medications: External hormone use, anti-androgen drugs

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Kisspeptin At diagnosis of CPP and 6 months after treatment of CPP ELISA,DLK1 At diagnosis of CPP and 6 months after treatment of CPP ELISA

Secondary Outcome Measures

Name	Time	Method
characteristics of CPP girls Baseline and after treatment of CPP Demographic data,Correlation of serum Kisspeptin and DLK1 levles At at diagnosis of CPP and 6 months after treatment Correlation